Staar Surgical Co. Aktie
39,20 €
Deine Einschätzung
Staar Surgical Co. Aktie
Was spricht für und gegen Staar Surgical Co. in den nächsten Jahren?
Pro
Kontra
Rendite von Staar Surgical Co. im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Staar Surgical Co. | -0,78 % | -1,78 % | -10,01 % | -33,06 % | 35,03 % | -60,44 % | - |
Orasure Tech | -2,45 % | 2,58 % | -1,65 % | -3,63 % | -35,84 % | -37,84 % | -39,61 % |
scPharmaceuticals | 6,70 % | 3,24 % | 6,70 % | -55,18 % | -22,43 % | -7,08 % | - |
SI-BONE Inc | 0,73 % | -3,50 % | -2,13 % | -42,50 % | -27,37 % | -45,67 % | - |
Kommentare
News
STAAR Surgical Reports First Quarter 2024 Results
STAAR Surgical Company (NASDAQ: K), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today
STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today
STAAR Surgical to Report First Quarter Results on May 7, 2024
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today